Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer
Federica Miglietta(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Eleonora Mioranza(Istituti di Ricovero e Cura a Carattere Scientifico), Grazia Maria Vernaci(University of Padua), Vassilena Tsvetkova(University of Padua), PierFranco Conte(University of Padua), Silvia Michieletto(Istituto Oncologico Veneto), Alice Menichetti(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Giovanni Faggioni(Istituto Oncologico Veneto), Michele Bottosso(University of Padua), Marcello Mele(University of Pisa), Maria Vittoria Dieci(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Elisa Genovesi(University of Padua), Tania Saibene(Istituti di Ricovero e Cura a Carattere Scientifico), Enrico Cumerlato(University of Padua)
Cited by 16
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830